Clinical Features, Virus Identification, and Sinusitis as a Complication of Upper Respiratory Tract Illness in Children Ages 4-7 Years - 24/03/16
Abstract |
Objective |
To determine the rate of sinusitis complicating upper respiratory tract illnesses (URIs) in children. We prospectively identified the clinical, virologic, and epidemiologic characteristics of URIs in a population of 4- to 7-year-old children followed for 1 year.
Study design |
This was an observational cohort study in 2 primary care pediatric practices in Madison, Wisconsin. Nasal samples were obtained during 4 asymptomatic surveillance visits and during symptomatic URIs. A polymerase chain reaction-based assay for 9 respiratory viruses was performed on nasal samples. A diagnosis of sinusitis was based on published criteria.
Results |
Two hundred thirty-six children ages 48-96 months were enrolled. A total of 327 URIs were characterized. The mean number of URIs per child was 1.3 (range 0-9) per year. Viruses were detected in 81% of URIs; rhinovirus (RV) was most common. Seventy-two percent of URIs were resolved clinically by the 10th day. RV-A and RV-C were detected more frequently at URI visits; RV-B was detected at the same rate for both asymptomatic surveillance visits and URI visits. Sinusitis was diagnosed in 8.8% of symptomatic URIs. Viruses were detected frequently (33%) in samples from asymptomatic children.
Conclusions |
Sinusitis occurred in 8.8% of symptomatic URIs in our study. The virus most frequently detected with URIs in children was RV; RV-A and RV-C detection but not RV-B detection were associated with illness. Viruses, especially RV, are detected frequently in asymptomatic children. Most URIs have improved or resolved by the 10th day after onset. Children experienced a mean of 1.3 URIs per year, which was lower than expected.
Le texte complet de cet article est disponible en PDF.Keyword : ADV, CoV, EV, FLU, GEE, hBoV, hMPV, PIV, RSV, RV, URI
Plan
| Funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01 AI097172). J.G. is supported by the National Institutes of Health, GlaxoSmithKline and Merck Inc; and serves as a consultant for GlaxoSmithKline, Johnson & Johnson, Merck Inc, Medimmune, Boehringer Ingelheim, Gilead, and Genentech. S.L. is supported by Broad Foundation, Janssen Inc, Sloan Foundation, and Pfizer Inc; received personal fees from Janssen, Boston Consulting Group, and Regeneron; has filed for or holds patents for reductive prodrug cancer chemothera (Stan449-PRV), combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa illnesses with royalties paid to KaloBios Inc, use of Lactobacillus sakei and other lactic acid bacteria as a therapeutic strategy for chronic rhinosinusitis, and the use of PhyloChip as a diagnostic and prognostic clinical tool pending. The other authors declare no conflicts of interest. |
Vol 171
P. 133 - avril 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
